Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Protein Page:
PSME2 (human)
rdtyret
p Phosphorylation
ac Acetylation
me Methylation
m1 Mono-methylation
m2 Di-methylation
m3 Tri-methylation
ub Ubiquitylation
sm Sumoylation
ne Neddylation
gl O-GlcNAc
ga O-GalNAc
pa Palmitoylation
ad Adenylation
sn S-Nitrosylation
ca Caspase cleavage
sc Succinylation

Overview
PSME2 Implicated in immunoproteasome assembly and required for efficient antigen processing. The PA28 activator complex enhances the generation of class I binding peptides by altering the cleavage pattern of the proteasome. Heterodimer of PSME1 and PSME2, which forms a hexadimeric ring. By IFNG/IFN-gamma. Belongs to the PA28 family. Note: This description may include information from UniProtKB.
Protein type: Protease; Proteasome complex
Chromosomal Location of Human Ortholog: 14q11.2
Cellular Component: cytoplasm; cytosol; membrane; nucleoplasm; proteasome activator complex; proteasome complex
Biological Process: activation of MAPKK activity; anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process; antigen processing and presentation of exogenous peptide antigen via MHC class I; antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; antigen processing and presentation of peptide antigen via MHC class I; apoptosis; axon guidance; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; epidermal growth factor receptor signaling pathway; fibroblast growth factor receptor signaling pathway; G1/S transition of mitotic cell cycle; gene expression; innate immune response; insulin receptor signaling pathway; MAPKKK cascade; mitotic cell cycle; negative regulation of apoptosis; negative regulation of ubiquitin-protein ligase activity during mitotic cell cycle; nerve growth factor receptor signaling pathway; polyamine metabolic process; positive regulation of ubiquitin-protein ligase activity during mitotic cell cycle; programmed cell death; protein polyubiquitination; Ras protein signal transduction; regulation of amino acid metabolic process; regulation of apoptosis; regulation of mRNA stability; regulation of ubiquitin-protein ligase activity during mitotic cell cycle; small GTPase mediated signal transduction; stimulatory C-type lectin receptor signaling pathway; T cell receptor signaling pathway; tumor necrosis factor-mediated signaling pathway; vascular endothelial growth factor receptor signaling pathway; viral reproduction
Reference #:  Q9UL46 (UniProtKB)
Alt. Names/Synonyms: 11S regulator complex beta subunit; 11S regulator complex subunit beta; Activator of multicatalytic protease subunit 2; cell migration-inducing protein 22; MCP activator, 31-kD subunit; PA28b; PA28beta; proteasome (prosome, macropain) activator subunit 2 (PA28 beta); Proteasome activator 28 subunit beta; proteasome activator 28-beta; Proteasome activator complex subunit 2; proteasome activator hPA28 subunit beta; PSME2; REG-beta; REGbeta
Gene Symbols: PSME2
Molecular weight: 27,402 Da
Basal Isoelectric point: 5.54  Predict pI for various phosphorylation states
Protein-Specific Antibodies or siRNAs from Cell Signaling Technology® Total Proteins
Select Structure to View Below

PSME2

Protein Structure Not Found.


STRING  |  cBioPortal  |  Wikipedia  |  Reactome  |  neXtProt  |  Protein Atlas  |  BioGPS  |  Scansite  |  Pfam  |  Phospho.ELM  |  NetworKIN  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene  |  InnateDB


Modification Sites and Domains  
Click here to view other types of protein modifications

Modification Sites in Parent Protein, Orthologs, and Isoforms  
 

Show Multiple Sequence Alignment


 LTP 

LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.


 HTP 

HTP: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.


       human

 
0 1 K3‑m2 _____MAkPCGVRLs
0 1 K3‑ub _____MAkPCGVRLs
0 10 S10‑p kPCGVRLsGEARkQV
0 2 K15 RLsGEARKQVEVFRQ
0 3 K15‑ub RLsGEARkQVEVFRQ
0 8 K39‑ub LYRFLPQkIIYLNQL
0 1 S102‑p PGNEKVLsLLALVkP
0 3 K108‑ub LsLLALVkPEVWTLk
0 1 K115‑ub kPEVWTLkEKCILVI
0 63 K145‑ub FGVAIQEkVLERVNA
0 1 K156 RVNAVKTKVEAFQTT
0 3 K180‑ac DAVAKASkETHVMDY
0 11 Y199‑p HERDEAAyGELRAMV
0 1 K231‑sc LEKIVNPkGEEKPSM
0 1 K235 VNPkGEEKPSMy___
0 134 Y239‑p GEEKPSMy_______
  mouse

 
K3 _____MAKPCGVRLs
K3 _____MAKPCGVRLs
S10‑p KPCGVRLsGEARkQV
K15‑ac RLsGEARkQVDVFRQ
K15‑ub RLsGEARkQVDVFRQ
K39 LCTFLPRKIISLSQL
A102 PGNEKLLALLALVKP
K108 LALLALVKPEVWTLK
K115 KPEVWTLKEKCILVI
K145‑ub FGVAIQEkVLERVNA
K156 RVNAVKTKVEAFQTT
K180‑ac DAVAKASkDTHVMDY
Y199 HERDEAAYGALRAMV
K231 LEKIVNPKGEEKPSM
K235 VNPKGEEKPSMy___
Y239‑p GEEKPSMy_______
  rat

 
K3 _____MAKPCGVRLS
K3 _____MAKPCGVRLS
S10 KPCGVRLSGEARkQV
K15‑ac RLSGEARkQVDAFRQ
K15 RLSGEARKQVDAFRQ
K39 LCTFLPRKIISLSQL
A101 PGNEKLLALLALVKP
K107 LALLALVKPEVWTLK
K114 KPEVWTLKEKCILVI
K144 FGVAIQEKVLERVNA
K155‑ac RVNAVKTkVEAFQTA
K179‑ac DAVAKASkDTHVMDY
Y198 HERDEAAYGALRAMV
K230 LEKIVNPKGEEkPSM
K234‑ac VNPKGEEkPSMY___
Y238 GEEkPSMY_______
Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.